Skip to main content
    T

    TG Therapeutics Inc (TGTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $62.76
    -1.75 (-2.71%)

    Market Cap: $9.75B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    TG Therapeutics Inc (TGTX) Financials: Revenue, Profit and Cash Flow

    Updated Aug 3, 2026. Financial statements from company filings, amounts in US dollars.

    TG Therapeutics reported revenue of $616.29M for the fiscal year ended Dec 31, 2025, up 87.3% from the year before. That year, net income was $447.18M with a net margin of 72.6%, operating cash flow was -$24.77M and free cash flow was -$24.99M. The quarter ended Jun 30, 2026 had revenue of $240.34M and net income of $7.78M.

    Revenue and Margins

    The operating margin was 20.0% in the fiscal year ended Dec 2025, the highest of the 3 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $152.00K, a compound annual rate of 151.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$616.29M+87.3%83.7%20.0%72.6%
    Dec 2024$329.00M+40.8%88.3%12.7%7.1%
    Dec 2023$233.66M+8290.0%94.0%8.8%5.4%
    Dec 2022$2.79M-58.4%100.0%-7839.0%-8036.3%
    Dec 2021$6.69M+4300.7%88.2%-5154.3%-5204.1%
    Dec 2020$152.00K0.0%100.0%-179996.1%-183803.3%
    Dec 2019$152.00K0.0%100.0%-111220.4%-113730.9%
    Dec 2018$152.00K0.0%100.0%-114736.8%-114132.9%
    Dec 2017$152.00K0.0%100.0%-78100.0%-77944.7%
    Dec 2016$152.00KN/A100.0%-51953.3%-51482.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 1812.7% from the year before. In the quarter ended Jun 2026, net income fell 72.4% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$616.29M$329.00M$233.66M$2.79M$6.69M$152.00K$152.00K$152.00K$152.00K$152.00K
    Cost of revenue$100.71M$38.49M$14.13M$0$790.00K$0$0$0$0$0
    Gross profit$515.57M$290.52M$219.53M$2.79M$5.90M$152.00K$152.00K$152.00K$152.00K$152.00K
    Research and development$160.22M$94.29M$76.19M$125.35M$222.58M$165.90M$154.18M$159.39M$102.53M$69.23M
    Operating income$123.32M$41.93M$20.63M-$218.32M-$344.77M-$273.59M-$169.06M-$174.40M-$118.71M-$78.97M
    Net income$447.18M$23.38M$12.67M-$223.81M-$348.10M-$279.38M-$172.87M-$173.48M-$118.48M-$78.25M
    EBITDA$131.79M$44.91M$26.24M-$211.59M-$340.37M-$271.78M-$166.79M-$172.50M-$117.36M-$78.05M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$240.34M$204.92M$192.57M$161.71M$141.15M$120.86M$108.19M$83.88M$73.47M$63.47M$43.97M$165.81M
    Gross profit$199.14M$171.41M$154.43M$133.62M$122.21M$105.31M$92.78M$74.54M$65.16M$58.03M$34.20M$162.31M
    Operating income$21.67M$34.80M$50.49M$29.36M$34.84M$8.62M$29.95M$12.43M$8.82M-$9.27M-$12.48M$114.78M
    Net income$7.78M$19.78M$23.04M$390.89M$28.19M$5.06M$23.33M$3.88M$6.88M-$10.71M-$14.42M$113.93M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $246.69M exceeded cash and equivalents by $167.54M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.06B$577.69M$329.59M$193.57M$379.63M$625.64M$163.01M$83.62M$97.38M$54.78M
    Current assets$630.76M$566.36M$317.94M$168.27M$330.96M$611.74M$149.15M$79.03M$93.32M$50.86M
    Cash and equivalents$79.15M$179.89M$92.93M$102.30M$298.89M$553.44M$112.64M$41.96M$56.72M$25.03M
    Total liabilities$415.23M$355.33M$169.09M$134.99M$142.48M$106.29M$124.40M$59.58M$30.39M$18.91M
    Short-term debt$1.04M$1.16M$1.45M$1.58M$975.00K$22.18M$0$67.00K$128.00K$68.88K
    Long-term debt$245.65M$244.43M$100.12M$71.14M$66.79M$7.72M$28.97M$0$0$0
    Shareholder equity$648.02M$222.36M$160.50M$58.59M$237.15M$519.35M$38.62M$24.04M$66.99M$35.87M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$1.64B$1.53B$1.06B$1.03B$702.61M$656.69M$577.69M$586.01M$401.21M$373.32M$329.59M$331.07M
    Total liabilities$1.04B$945.71M$415.23M$417.81M$426.18M$419.40M$355.33M$393.86M$223.64M$213.21M$169.09M$166.30M
    Cash and equivalents$482.57M$442.21M$79.15M$74.08M$129.13M$132.14M$179.89M$195.82M$82.91M$75.48M$92.93M$150.90M
    Shareholder equity$604.08M$583.13M$648.02M$607.22M$276.43M$237.29M$222.36M$192.16M$177.57M$160.11M$160.50M$164.77M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$24.77M-$40.52M-$31.41M-$176.17M-$295.63M-$214.51M-$132.81M-$128.93M-$93.76M-$63.15M
    Capital expenditures$214.00K$45.00K$0$14.00K$401.00K$357.00K$131.00K$90.00K$2.00K$344.00K
    Free cash flow-$24.99M-$40.56M-$31.41M-$176.18M-$296.04M-$214.86M-$132.94M-$129.01M-$93.76M-$63.50M
    Share repurchases$91.24M$8.76M$0$0N/AN/AN/AN/AN/AN/A
    Investing cash flow$13.80M-$1.04M-$50.65M-$20.01M-$332.00K-$24.51M-$718.00K$1.18M-$8.21M$26.55M
    Financing cash flow-$89.73M$128.53M$72.70M-$391.00K$41.42M$679.83M$204.21M$113.64M$133.66M$5.02M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow$39.26M-$17.89M$19.66M-$23.15M$7.44M-$28.71M-$25.64M-$12.21M$5.54M-$8.21M-$13.21M$83.70M
    Capital expenditures$293.00K$51.00K$67.00K$80.00K$42.00K$25.00K$21.00K$24.00K$0$0$0$0
    Free cash flow$38.97M-$17.95M$19.59M-$23.23M$7.39M-$28.74M-$25.66M-$12.23M$5.54M-$8.21M-$13.21M$83.70M
    Last 12 quarters

    Frequently Asked Questions About TGTX

    What is TG Therapeutics' annual revenue?

    TG Therapeutics reported revenue of $616.29M for the fiscal year ended Dec 31, 2025.

    How fast is TG Therapeutics' revenue growing?

    Revenue was up 87.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 504.9%.

    Is TG Therapeutics profitable?

    Yes. TG Therapeutics reported net income of $447.18M for the fiscal year ended Dec 31, 2025, with a net margin of 72.6%.

    How much free cash flow does TGTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$24.77M minus capital expenditures of $214.00K produced free cash flow of -$24.99M.

    How much debt does TG Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $245.65M, short-term debt of $1.04M and cash and equivalents of $79.15M.